{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:53:07Z","timestamp":1792155187114,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.cmi.2019.10.029","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T21:29:45Z","timestamp":1574198985000},"page":"436-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity"],"prefix":"10.1016","volume":"26","author":[{"given":"B.R.","family":"Dalton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rajakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ondro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sabuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Griener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dersch-Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rennert-May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.10.029_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.cmi.2019.10.029_bib3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infectious by Staphylococcus aureus","volume":"57","author":"Moise","year":"2000","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.cmi.2019.10.029_bib4","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib5","first-page":"828","article-title":"Making the change to area under the curve-based vancomycin dosing","volume":"75","author":"Heil","year":"2018","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.cmi.2019.10.029_bib6","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0895-4356(90)90068-Z","article-title":"The use of risk factors in medical diagnosis: opportunities and cautions","volume":"43","author":"Boyko","year":"1990","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2019.10.029_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cca.2014.11.027","article-title":"A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy","volume":"440","author":"Suzuki","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cmi.2019.10.029_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jcpt.12399","article-title":"Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia","volume":"41","author":"Fukumori","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cmi.2019.10.029_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jcph.653","article-title":"Pharmacokinetic characteristics and clinical outcomes of vancomycin in young children","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2019.10.029_bib13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? a pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2019.10.029_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0214309","article-title":"The association of vancomycin trough levels with outcomes among patients with methicillin-resistant Staphylococcus aureus (MRSA) infections\u202f: retrospective cohort study","volume":"14","author":"Yahav","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2019.10.029_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.cmi.2019.10.029_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0895-4356(90)90159-M","article-title":"High agreement but low kappa: II. Resolving the paradoxes","volume":"43","author":"Cicchetti","year":"1990","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2019.10.029_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cmi.2019.10.029_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1536867X0900900203","article-title":"Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression","volume":"9","author":"Harbord","year":"2009","journal-title":"Stata J"},{"key":"10.1016\/j.cmi.2019.10.029_bib19","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/sim.942","article-title":"A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations","volume":"20","author":"Rutter","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2019.10.029_bib20","first-page":"530","article-title":"Efficacy of vancomycin for methicillin-resistant Staphylococcus aureus strains with minimum inhibitory concentration of 1 and 2 mcg\/mL in the Prompt method using a MicroScan Pos Combo 3.1J panel. [Japanese]","volume":"64","author":"Tagui","year":"2016","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib21","first-page":"149","article-title":"Report of 6 cases of vancomycin-treated blood stream infection under therapeutic drug monitoring. [Chinese]","volume":"15","author":"Zhang","year":"2015","journal-title":"Chin J Infect Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib22","first-page":"220","article-title":"Evaluation of the usefulness of vancomycin dosage design based on pharmacokinetics\/pharmacodynamics theory. [Japanese]","volume":"55","author":"Sato","year":"2007","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib23","first-page":"297","article-title":"Clinical significance of pharmacokinetic\/pharmacodynamic variables using Monte Carlo simulation in vancomycin treatment of pulmonary methicillin-resistant Staphylococcus aureus infection. [Japanese]","volume":"53","author":"Inagaki","year":"2005","journal-title":"Jpn J Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2019.10.029_bib24","first-page":"S107","article-title":"Pharmacokinetic analysis of continuous infusion of vancomycin in critically ill children","volume":"6","author":"Genuine","year":"2016","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.cmi.2019.10.029_bib25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/0897190016658584","volume":"29","author":"Martinez","year":"2016","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.cmi.2019.10.029_bib26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-014-0164-z","article-title":"Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis","volume":"53","author":"Mangin","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2019.10.029_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1345\/aph.1P495","article-title":"Outcomes associated with AUC24\/MIC nomogram dosing of vancomycin","volume":"45","author":"Michalets","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2019.10.029_bib28","first-page":"197","article-title":"Impact of a bayesian pharmacokinetic dosing programme of vancomycin on clinical outcomes","author":"Moreno Santamaria","year":"2016","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.cmi.2019.10.029_bib29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jcla.21883","article-title":"Vancomycin AUC24\/MIC ratio in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"30","author":"Ji","year":"2016","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.cmi.2019.10.029_bib30","first-page":"1","article-title":"Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest \u00ae macromethod among patients with MRSA bloodstream infections\u202f: a pilot study","author":"Martirosov","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2019.10.029_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/CIA.S52259","article-title":"The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia","volume":"8","author":"Mizuno","year":"2013","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.cmi.2019.10.029_bib33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ijantimicag.2015.09.010","article-title":"Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"46","author":"Song","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.10.029_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration\u2013time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.10.029_bib36","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/CIA.S50238","article-title":"Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia","volume":"8","author":"Mizokami","year":"2013","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.cmi.2019.10.029_bib37","series-title":"Cochrane handbook for systematic reviews of diagnostic test accuracy","first-page":"1","article-title":"Chapter 10; Analysing and Presenting Results","author":"Macaskill","year":"2010"},{"key":"10.1016\/j.cmi.2019.10.029_bib38","first-page":"284","article-title":"Continuous vs. intermittent vancomycin therapy","volume":"3","author":"Duszynska","year":"2016","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.cmi.2019.10.029_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin resistant Staphylococcus aureus bacteremia","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cmi.2019.10.029_bib40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10096-010-1024-x","article-title":"The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia","volume":"29","author":"Shime","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.23736\/S0026-4946.16.04688-0","article-title":"Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs","volume":"70","author":"Arun","year":"2018","journal-title":"Minerva Pediatr"},{"key":"10.1016\/j.cmi.2019.10.029_bib42","doi-asserted-by":"crossref","DOI":"10.23736\/S0026-4946.18.04978-2","article-title":"Influence of pharmacokinetic\/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia","author":"Ruiz","year":"2018","journal-title":"Minerva Pediatr"},{"key":"10.1016\/j.cmi.2019.10.029_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1378\/chest.130.4.947","article-title":"Predictors of mortality for methicillin resistant Staphylococcus aureus health care associated pneumonia","volume":"130","author":"Jeffres","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2019.10.029_bib45","first-page":"1","article-title":"Coagulase negative staphylococcal sepsis in neonates\u202f: do we need to adapt vancomycin dose or target\u202f?","author":"Padari","year":"2016","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.cmi.2019.10.029_bib46","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1093\/cid\/ciy667","article-title":"Model-based evaluation of the clinical and microbiological efficacy of Vancomycin: a prospective study of Chinese adult in-house patients","volume":"67","author":"Shen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib47","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections\u202f: prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2010.02.026","article-title":"Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"67","author":"Neuner","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12882-017-0581-y","article-title":"Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function\u202f: a retrospective, cohort analysis","volume":"18","author":"Liu","year":"2017","journal-title":"BMC Nephrol"},{"issue":"12","key":"10.1016\/j.cmi.2019.10.029_bib50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration\u2013time curve: a cross-sectional survey of a national health consortium","volume":"76","author":"Kufel","year":"2019","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.cmi.2019.10.029_bib51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration\u2013guided dosing to area under the curve\u2013guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.10.029_bib52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","article-title":"Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus -associated septic shock","volume":"41","author":"Zelenitsky","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.10.029_bib53","first-page":"2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Am Med Assoc"},{"key":"10.1016\/j.cmi.2019.10.029_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC(0\u201324) threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib55","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experimental to study the impact of vancomycin area under the concentration time curve guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.cmi.2019.10.029_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.cmi.2019.10.029_bib57","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney Injury\u202f: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib58","first-page":"1","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE)","author":"Lodise","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.10.029_bib59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijantimicag.2013.01.009","article-title":"Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects","volume":"41","author":"Ampe","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.10.029_bib60","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1128\/AAC.02714-15","article-title":"Vancomycin 24-hour area under the curve\/minimum bactericidal concentration ratio as a novel predictor of mortality in methicillin- resistant Staphylococcus aureus bacteremia","volume":"60","author":"Britt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC 24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib62","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program\u2019s retrospective evaluation of vancomycin auc24\/mic and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2019.10.029_bib63","doi-asserted-by":"crossref","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0\u201324\/MIC BMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.10.029_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01602-17","article-title":"Pharmacokinetic\/Pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia","volume":"62","author":"Jumah","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.10.029_bib65","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","article-title":"Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19305841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19305841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:24:50Z","timestamp":1761117890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19305841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1198743X19305841"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.10.029","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}